Other
Stock-Based Comp
Roivant Sciences Stock-Based Comp decreased by 26.5% to $77.17M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.6%, from $83.49M to $77.17M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows a downward trend with a -11.5% CAGR.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2020
Last reportedQ4 2025May 20, 2026
Metric ID:
other_share_based_compensationHistorical Data
20 periods
| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.27M | $397.31M | $71.22M | $77.16M | $72.79M | $61.98M | $57.73M | $25.28M | $49.26M | $49.32M | $54.33M | $46.72M | $50.19M | $71.67M | $83.68M | $83.49M | $82.18M | $81.82M | $105.00M | $77.17M |
| QoQ Change | — | >999% | -82.1% | +8.3% | -5.7% | -14.9% | -6.9% | -56.2% | +94.9% | +0.1% | +10.2% | -14.0% | +7.4% | +42.8% | +16.8% | -0.2% | -1.6% | -0.4% | +28.3% | -26.5% |
| YoY Change | — | — | — | — | +277.8% | -84.4% | -18.9% | -67.2% | -32.3% | -20.4% | -5.9% | +84.8% | +1.9% | +45.3% | +54.0% | +78.7% | +63.7% | +14.2% | +25.5% | -7.6% |
Range$19.27M – $397.31M
CAGR+33.9%
Avg YoY Growth+25.6%
Median YoY Growth+8.0%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|
| Reportable Segment | $71.08M | $70.83M | $86.87M | $69.52M |
| Total | $82.18M | $81.82M | $105.00M | $77.17M |
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's stock-based comp?
- Roivant Sciences (ROIV) reported stock-based comp of $77.17M in Q1 2026.
- How has Roivant Sciences's stock-based comp changed year-over-year?
- Roivant Sciences's stock-based comp decreased by 7.6% year-over-year, from $83.49M to $77.17M.
- What is the long-term trend for Roivant Sciences's stock-based comp?
- Over 4 years (2021 to 2025), Roivant Sciences's stock-based comp has grown at a -11.5% compound annual growth rate (CAGR), from $564.96M to $346.17M.